Whole-exome sequencing of 109 pancreatic ductal adenocarcinoma (PDA) cases revealed significant genetic diversity and therapeutic targets. The study identified multiple mutated genes, including RBM10, which was associated with longer survival despite aggressive histological features. KRAS mutations were common, but codon Q61 alleles were linked to improved survival. Oncogenic BRAF mutations were mutually exclusive with KRAS and showed sensitivity to vemurafenib. High-frequency alterations in Wnt, chromatin remodeling, Hedgehog, DNA repair, and cell cycle pathways were observed. These findings highlight the genetic complexity of PDA and provide insights into prognostic factors and potential therapeutic targets. The study also identified MYC amplification as a poor prognostic indicator and associated with adenosquamous subtype. Additionally, mutations in genes like GNAS, TP53, CDKN2A, and SMAD4 were confirmed as key drivers in PDA. The research underscores the importance of genetic analysis in understanding PDA's etiology and developing targeted therapies. The study also found that certain genetic alterations, such as ARID1A loss, were linked to poor outcomes, while others, like RBM10 mutations, were associated with better survival. The findings suggest that genetic profiling could identify subsets of PDA patients who may benefit from targeted therapies, particularly those involving the KRAS/BRAF axis. The study emphasizes the need for further research into the genetic mechanisms underlying PDA and the development of personalized treatment strategies.Whole-exome sequencing of 109 pancreatic ductal adenocarcinoma (PDA) cases revealed significant genetic diversity and therapeutic targets. The study identified multiple mutated genes, including RBM10, which was associated with longer survival despite aggressive histological features. KRAS mutations were common, but codon Q61 alleles were linked to improved survival. Oncogenic BRAF mutations were mutually exclusive with KRAS and showed sensitivity to vemurafenib. High-frequency alterations in Wnt, chromatin remodeling, Hedgehog, DNA repair, and cell cycle pathways were observed. These findings highlight the genetic complexity of PDA and provide insights into prognostic factors and potential therapeutic targets. The study also identified MYC amplification as a poor prognostic indicator and associated with adenosquamous subtype. Additionally, mutations in genes like GNAS, TP53, CDKN2A, and SMAD4 were confirmed as key drivers in PDA. The research underscores the importance of genetic analysis in understanding PDA's etiology and developing targeted therapies. The study also found that certain genetic alterations, such as ARID1A loss, were linked to poor outcomes, while others, like RBM10 mutations, were associated with better survival. The findings suggest that genetic profiling could identify subsets of PDA patients who may benefit from targeted therapies, particularly those involving the KRAS/BRAF axis. The study emphasizes the need for further research into the genetic mechanisms underlying PDA and the development of personalized treatment strategies.